A new prefilled autoinjector pen for diabetics, Ogluo (glucagon) has been launched in Germany by Tetris Pharma, a subsidiary of British firm Arecor Therapeutics (AIM: AREC).
The specially designed, ambiently stored preparation has been approved for the treatment of severe hypoglycemia in children and adults living with diabetes.
Hypoglycemia is a major possible side effect of insulin, with severe forms of the condition representing a serious threat to the health of diabetics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze